Complex rehabilitative care is that which requires more time, skill, and cost than the rehabilitative procedures classified under the previous levels. Most of this care would require referral to a specialist for complex treatment. These services may not predictably improve the overall prognosis of many patients. Example: Periodontal surgery Complex surgery TJM ; Maxillary and mandibular resection surgery and pilocarpine.
Croce, Florence, c. 1336-1338 ; , showed an angel holding a spatially rendered armillary sphere. By the sixteenth century the books sometimes contained actual cardboard models of the instruments, the Astronomicon Cesareum of Apianus 1540 ; being an example par excellence. Hand in hand with this trend towards a visual illustration of the instruments was a trend to represent the projection methods that they entailed. These new links between theory and practice took many forms. In the last decade of the fourteenth century when Blasius of Parma was teaching optics at Padua, he had his students read Ptolemy's Planisphere and asked them to demonstrate its principles using candles to project light onto an armillary sphere and observe its projected shadows on the wall. Optics, which had once been a question of philosophical debate or of abstract geometrical diagrams, now required physical demonstrations which could be recorded as representations. Hence aside from their obvious role in the certification of observation, instruments had a deeper role in shifting attention from observation per se to representation of what it was that they were used to observe. It was no longer enough to see accurately: what was seen had to be recorded and demonstrated. That was ultimately what inspired Brunelleschi's experiments and led eventually to a split in the meaning of optics perspectiva ; . The theory of how we see accurately became optics: the practice of how we represent what we see accurately became linear ; perspective. Optics was thought of as the theory of perspective, linear perspective as the practical application. Hence why treatises on linear perspective were frequently called the Practice of perspective, Practical perspective etc., although more conservative authors continued to refer to both the theory of vision and the practice of representation using a single term perspectiva or optica ; , and indeed continued to refer to Witelo as a fundamental source even into the seventeenth century.238 14. Re-definition of Knowledge It is important to recognize, however, that linear perspective was much more than the practical application of optical theory. It came about through a basic shift, first in the organization, and then in the actual definition of knowledge itself. When William of Moerbeke made his translations of Archimedes, Eutocius, Hero and Ptolemy in 1269, these short works were bound together in a single manuscript. There were practical reasons for this. The treatises and or fragments were often short and thus were conveniently bound together. This applied equally to the optical texts. In rare cases a compendium of treatises would be almost entirely limited to optics as for example: Ptolemy's Optics, Bacon's Optics, Albertus Magnus' Question on the form resulting in a mirror, Tideus' On mirrors, Alkindi's Optics, Malfegyr's On twilight and PseudoEuclid's On mirrors Paris, Bibliothque Nationale, Ms. Lat. 10260 ; . In most cases, however, compendia contained optical treatises along with other subjects such as mechanics and water. For instance, one manuscript Vatican, Ms. Lat. 2975 ; , contains the above works by Ptolemy, Bacon, Albertus Magnus, Tideus, Malfegyr and two versions of a work On weights and balances attributed to Euclid, Thebit Ibn Qurra's On weights and measures and Philon's Pneumatics. There were many combinations of themes. Sometimes it was optics and geometry e.g. Vatican, Lat. 3102 ; , or optics and astronomy e.g. Vatican, Lat. 4082 ; or optics and instruments e.g. Vatican, Pal. Lat. 1377. Glabrata tested demonstrated minimal photofrin uptake under conditions favorable for uptake by c and pima. [PICTURE OF LEON F. GOSSELIN] LEON F. GOSSELIN, Chairman of the Board, President and Chief Executive Officer, Axcan Pharma Inc. President and Chief executive officer's Report DEAR SHAREHOLDERS, During the second quarter of fiscal 2001, Axcan's revenues rose almost 58% and EBITDA rose close to 200% for the same period, reflecting our continued increase in market penetration in the United States. We are very encouraged by our performance in the first half and are confident that we will be able to meet our objectives for the year. These results validate our marketing strategy and reflect the quality of our sales force in Canada and the United States. Because of its broad line of gastroenterology products in both Canada and the United States, Axcan has solidified its leadership position in North America in this field. Our intention now is to reinforce that position even further, to continue to develop our pipeline and to gradually move into the promising European market. HIGHLIGHTS OF THE QUARTER - CANASA 500 mg mesalamine 5-ASA ; rectal suppositories were approved by the FDA following an expedited review. These suppositories, indicated for the treatment of active ulcerative proctitis, were launched in April and are marketed through Axcan's own specialized sales and marketing organization. The total market for mesalamine suppositories is approximately US$ 20 million. - Axcan recently announced the U.K. launch of PHOTOFRIN for the palliative treatment of late-stage lung cancer and advanced oesophageal cancer, following the granting of full marketing authorization by the U.K. authorities. This will allow Axcan to actively market PHOTOFRIN that was only available on a named-patient basis since its approval. PHOTOFRIN is already marketed by Axcan in Canada and the United States. It is also marketed in Japan by a local distributor and is available on a named-patient basis in 16 European countries. There are currently over 150 PDT centres using PHOTOFRIN worldwide and thousands of patients have already been treated with PHOTOFRIN for various diseases. - Axcan expanded its intellectual property base by licensing rights for a series of ursodiol formulations and compounds that may replace URSO 250 in Axcan's liver disease development programs and related studies. FINANCIAL RESULTS Revenue for the second quarter ended March 31, 2001, all amounts are in U.S. dollars ; was .6 million compared to .6 million for the same period of the preceding year, a 58% increase. In the first quarter of last year, Axcan sales included an unusually high volume caused by Y2K concerns. As a consequence, sales in the second quarter of the year ended September 30, 2000, were affected by inventory drawdowns of wholesalers. For the six-month period ended March 31, 2001, revenue was .0 million compared to .9 million for the corresponding period in fiscal 2000, an increase of 20%. Sales of PHOTOFRIN, a product acquired by Axcan in June of 2000, contributed to this increase. Fluid filled vinyl pack may be heated or cooled for thermal therapy. 1-9 10 + Eyes Pack Green 175-00CE102-00 . 15.00 . 13.00 Eyes Pack Red 175-00CE101-00 . 15.00 . 13.00 Eyes Pack Jr. Green 175-00CE102-JR 12.00 . 11.40 Eyes Pack Single Aqua 175-00CE100-00 . 9.00 . 8.55 sold Individually and pindolol.

Burgeoning Global Industry Biotechnology is one of the world's fastest growing industries. Its greatest impact, both in Canada and worldwide, is in health care, including biopharmaceuticals. More than 90 percent of the advanced biotechnology products on the world market are health-related. It is expected that about three quarters of world biotechnology demand will continue to be in the health sector. Within the health sector, the biopharmaceutical segment promises major social and economic benefits. Its medicines, vaccines and other health-related devices and products have helped to reduce or eradicate many diseases and to improve life expectancy. Economically, world sales of biopharmaceuticals have grown more than seven-fold over the past decade, and should exceed $US18 billion by 2003. The biopharmaceutical portion of world prescription drug sales is expected to triple from the current 5 percent to 15 percent by 2005. Canada is well positioned to be an important player in this transition. Of the 24 biopharmaceuticals approved for sale on the world market, three emanate from Canadian firms: 3TC by BioChem Pharma Inc. for the treatment of HIV AIDS; Photofrin by QLT PhotoTherapeutics Inc. for the treatment of various cancers; and, Truquant BR by Biomira Diagnostics Inc. for the detection of breast cancer. Canada is poised for rapid growth in the commercialization of new biotechnology applications. A January 2000 survey of selected biopharmaceutical firms conducted by the Medical Research Council of Canada found that this group had over 400 products in the pipeline at that time. Canadian Biotechnology A Success Story Canada has become a biotechnology success story. Over the past several years, Canadian governments, the research community and industry have combined to create a strong infrastructure for a prosperous biotechnology future. Building on this base, the Canadian industry has achieved international recognition for the development of several important products, particularly in health care and agriculture. Like many forward thinking nations, Canada started investing in biotechnology research in the 1980s and is now building on its strengths. An important government goal is to position Canada as an ethically and socially responsible world leader in the development, commercialization, sale and use of biotechnology products and services. A 1997 survey by Statistics Canada in collaboration with Industry Canada and the association BIOTECanada indicated that the industry at that point consisted of 282 core companies, of which almost half were in the health sector. That industry snapshot showed employment of almost 10, 000 people, revenues of more than .1 billion [Unless otherwise indicated, dollars are expressed in Canadian currency], and R&D spending exceeding 5 million. Exports totalled 0 million annually. More recently Industry Canada identified 102 additional biotechnology companies which have been formed from 1997 onward, most of these in the health sector. While Canada's biotechnology industry sales are still small in the global context, this Canadian sector is dynamic and growing rapidly by 25 percent or more per year. In absolute numbers, Canada ranks second in terms of number of companies using. To be accented. Then, IC and TF * IDF are calculated. After this, the effectiveness of informativeness in accent placement is verified using the speech corpus. Each word in the speech corpus has an IC score, a TF * IDF score, a part-of-speech POS ; tag and a pitch accent label. Both IC and TF * IDF are used to test the correlation between informativeness and accentuation. POS is also investigated by several machine learning techniques in automatic pitch accent modeling and pramlintide.

The MAP kinase kinases MEK1 and MEK2, and in turn the extracellular signal-regulated kinases ERK1 and ERK2 2 ; . In recent years, it has become clear that Ras also controls the activity of other downstream effectors in addition to Raf-1. Ras has been shown to interact with and stimulate the activity of the catalytic p110 subunit of different isoforms of phosphatidylinositol 3-kinase PI 3-kinase ; 18 ; . In addition, overexpression of the dominant negative N17 Ras mutant inhibits insulin, platelet-derived growth factor, and epidermal growth factorstimulated Akt activation 19 ; . These findings suggest that Ras is an upstream activator of the PI 3-kinase Akt pathway. Grb10 is a pleckstrin homology and Src homology 2 SH2 ; domain-containing protein that binds to the autophosphorylated IR 20 ; . and others have shown that Grb10 binds to autophosphorylated tyrosine residues in the activation loop of the IR 21, 22 ; . In addition, a human Grb10 isoform with a deletion in the pleckstrin homology domain inhibits insulinstimulated tyrosine phosphorylation of the 60-kDa GAP-associated protein when overexpressed in CHO IR cells 23 ; . However, the identity of this GAP-associated protein and the mechanism by which Grb10 inhibited its tyrosine phosphorylation remained unknown. Very recently, it has been shown that Grb10 inhibits the catalytic activity of the IR in vitro 24 ; . These findings suggest that the binding of Grb10 to the activation domain of the IR blocks the ability of the receptor to phosphorylate its exogenous substrates. In the present study, we investigated the insulin-stimulated tyrosine phosphorylation of the 60-kDa GAP-associated protein. We provide evidence that this 60-kDa GAP-associated protein is in fact p62dok. In addition, we show that p62dok is a direct substrate of the IR with phosphorylation occurring mainly at tyrosine residues 362 and 398. Replacing tyrosine residues of p62dok at 362 and 398 with phenylalanine inhibited the interaction between p62dok and GAP. We also found that overexpression of wild-type p62dok in CHO IR cells inhibited insulin-stimulated activation of Ras, MAP kinase, and Akt. Furthermore, inhibition of Ras and Akt could be rescued by mutating 362 and 398 of p62dok. Taken together, our findings suggest that the IR-mediated tyrosine phosphorylation of p62dok plays important and specific roles in regulating the insulin-mediated MAP kinase and PI 3-kinase pathways downstream of Ras.
DNASequencing-TheDNA sequence was determined by the dideoxy chain-termination method 25 ; after subcloning into M13 mplO and m p l DNA-sequencing kit Takara Shuzo, Kyoto ; was used under the conditions recommended by the supplier. Enzyme Assays-The membrane fraction of the yeast cells was prepared as described previously 15 ; and used as the enzyme to assay the phospholipid-methylating activities. The phospholipid-methylating activities were determined by measuring the methylation of PE endogenously presentin the enzyme preparation, or exogenously added PMME or PDME with [methyl-"C]AdoMet. The basal reaction mixture contained 40 m Tris-HC1, pH 8.8, 0.25 m [methylM M M "CIAdoMet 150 dpm nmol ; , 3 m MgSO4, and enzyme 0.5 mgof protein ; in a total volume of 1.0 ml. This mixture was used to assay the PE-methylating activity. For estimation of thePMME-and PDME-methylating activities, this mixture was supplemented with PMME and PDME a t the concentration of0.3mM, respectively. After 15 min of incubation at 25 "C, the reaction was terminated by the addition of 0.5 ml of 2 HCI. The lipid products were extracted with 1 ml of chloroform methanol 2: 1, v v ; The organic phase was washed twice with 1 ml of methanol, 0.145 M NaCl l: l, v v ; and then evaporated to dryness. The lipids weremixed with standard phospholipids and then chromatographed on a Silica Gel 60 plate Merck ; with chloroform methanol acetic acid 88% formic acid water 35: 15: 6: v v asthe solvent. The lipids were visualized with I, vapor. The bands containing PMME, PDME, and PC were scraped into vials and then their radioactivities were counted in a toluene-TritonX-100 scintillant. The reaction proceeded linearly with time. Phospholipid Composition-Phospholipids were determined by counting their radioactivities after labeling cells with 32Pi 0.56 mCi mmol ; . Phospholipids were extracted from the cells by the method of Hosaka and Yamashita 26 ; with some modifications as follows. Cells were collected on Whatman GF Cglass-microfiberpaper by filtration and then washed twice with 5 ml of 0.145 M NaCI. The glass filter was soaked in 2 ml methanol containing 2 g of 0.1-mm diameter glass beads, sonicated for 5 min on ice with an Ohtake 5202 sonicator at an output of 50 watts and then mixed with 4 ml of chloroform. The resultant mixture was filtered through GF C glass-microfiber paper. The residue was extracted again with 3 mlof chloroform methanol 2: 1, v v ; The combined extracts were washed with 1 ml of 0.145 M NaCl and thentwice with 3 ml of methanol, 0.145 M NaCl l: l, v v ; The lipid extract was evaporated to dryness and then separated by two-dimensional thin-layer chromatography on a Silica Gel 60 plate using chloroform methanol water 65: 254, v v v ; for the first dimension and n-buthanollacetic acid water 3: 1: v for the second dimension 11 ; .The lipids were visualized with Ip vapor. Each phospholipid spot was scraped into a vial and then its radioactivity was counted in a toluene-TritonX-100 scintillant.

The studies in the ISPOR database cover the following topics: clinical outcome studies n 256 ; , cost studies n 2031 ; , healthcare use and policy studies n 888 ; , method and concept studies n 854 ; and patient-reported outcome n 656 ; . Therefore, cost and healthcare use and policy studies represent 62% of all the abstracts contained in the ISPOR database. Between 1998 and 2004, 8% of all abstracts related to cancer: 21 clinical outcomes studies, 187 cost studies, 34 healthcare use and policy studies, 60 method and concept studies and 53 patient-reported outcome studies. Therefore, cost and healthcare use and policy studies represent 62% of all the ISPOR cancerrelated abstracts. Colorectal cancer, breast cancer, NSCLC and NHL constitute 46% of all cancer studies. Table 6.7 shows the distribution of policy and cost studies within the different cancer types and pilocarpine.
Effects of varying [Ca2 ]o The analyses described in the preceding text were done in conditions of 0 [Ca2 ]o. Here we use the model to interpret intriguing experimental evidence Su et al. 2001 ; that reducing [Ca2 ]o, but not blocking Ca2 currents and Ca2 -activated K currents, may transfer a nonbursting cell into a burster. Clearly raising [Ca2 ]o will modify the neuronal dynamics by introducing voltage-gated Ca2 currents and Ca2 -activated K currents. In addition, raising [Ca2 ]o will shift the voltage dependence of INaP activation back toward more positive potentials Li and Hatton 1996; Yue et al. 2005 ; . Figure 9, A--C, illustrates the firing patterns of the neuron model obtained for three sets of parameters p is the half-maximum potential of the persistent sodium current ; : gCa 0.08 mS cm2, 41 mV Fig. 9A ; , gCa 0.05 mS cm2, p 44 mV p Fig. 9B ; , and gCa 0.02 mS cm2, p 46 mV Fig. 9C ; . The parameter set in Fig. 9A represents parameter values of physiological [Ca2 ]o, whereas those in Fig. 9BC represent parameters values of reduced [Ca2 ]o. The firing pattern of the neuron model obtained for the set gCa 0, p 47 mV, 0, has already been presented in corresponding to [Ca2 ]o Fig. 6D. It can be seen that reducing [Ca2 ]o augments burstiness in this model.

The Clinical Embryologist is pleased to announce that future issues will now be available internationally. This increase in circulation will bring wider coverage for articles submitted to our journal, as well as broaden the source of important research taking place around the world. In order to make this possible, we will be charging a nominal subscription fee of US.00 per year, for four issues, to cover shipping and handling. We hope this will meet the needs of our colleagues overseas. A subscription form will be made available. Please refer to our website for further information on how to subscribe through the internet. : embryologists.
Community dispatch brand names synonyms : porfimer is also known by the following brand names and or synonymsdhe; dhp ether; dihematoporphyrin ether; photofrin; porfimer; porfimer sodium drug category : porfimer is categorized under the following by the fda: dermatologic agents; antivirals; antineoplastic agents; atc: l01xd01 dosage forms : powder for solution absorption : not available interactions : drugbank: interactions for porfimer interactions for porfimer: there have been no formal interaction studies of photofrin ® and any other drugs.